Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials. (PubMed, Blood) - Oct 7, 2026 - P3 | "Here, we analyzed telomere length using qPCR in 917 samples from treatment-naïve CLL patients without TP53 aberrations enrolled in the GAIA/CLL13 trial comparing venetoclax-based combinations with rituximab (RV), obinutuzumab (GV), or obinutuzumab plus ibrutinib (GIV) versus chemoimmunotherapy (CIT). These findings propose telomere length as a prognostic marker for PFS in CLL patients receiving venetoclax-based first-line therapy and could be of relevance for risk stratification in the modern treatment era. NCT02950051."
IO biomarker • Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IGH • NFKBIE • NOTCH1 • RPS15 • SF3B1 • TP53
|
|
Anna-Maria Fink; Arnon P Kater; Barbara F Eichhorst; Billy Michael Chelliah Jebaraj; Can Zhang; Carsten Utoft Niemann; Caspar da Cunha-Bang; Christof Schneider; Deyan Yordanov Yosifov; Eugen Tausch; Henriette Huber; Karl-Anton Kreuzer; Kirsten Fischer; Mark-David Levin; Matthias Ritgen; Michael Gregor; Michael J Hallek; Moritz Fürstenau; Patrick Thornton; Philipp B Staber; Sandra Robrecht; Stephan Stilgenbauer; Tamar Tadmor
|